Polymyalgia Rheumatica
Polymyalgia rheumatica (PMR) is a chronic inflammatory disorder primarily affecting individuals aged 50 years and older. As a leading provider of drug and therapy development services in the field of autoimmune diseases and inflammation, our company is committed to advancing the therapeutics of PMR.
Overview of Polymyalgia Rheumatica
Polymyalgia rheumatica is an autoimmune condition that primarily affects the musculoskeletal system. It is characterized by symmetrical pain and stiffness in the shoulders, neck, and pelvic girdle region. Several studies have implicated pro-inflammatory cytokines, such as interleukin-6 (IL-6), in the pathogenesis of PMR. Elevated levels of IL-6 have been observed in the serum and synovial fluid of PMR cases, suggesting its potential role in disease progression. Additionally, genetic studies have identified specific human leukocyte antigen (HLA) alleles associated with an increased risk of developing PMR.
Fig.1 The pathophysiology of polymyalgia rheumatica. (Lundberg I. E., et al., 2022)
Therapy Discovery and Development for Polymyalgia Rheumatica
The current primary approach to treating polymyalgia rheumatica (PMR) is the administration of oral glucocorticoids (GCs). However, the prolonged use of GCs can lead to various detrimental effects, including osteoporosis, diabetes, and cardiovascular complications. As an alternative, disease-modifying antirheumatic drugs (DMARDs) present potential therapeutic options for PMR. Methotrexate (MTX), an immunosuppressive DMARD, has demonstrated promising results in reducing relapse risk and facilitating the discontinuation of GCs in PMR cases.
With our extensive range of expertise in therapeutic development, our company is dedicated to delivering professional solutions for polymyalgia rheumatica (PMR). If you desire further information on our specialized PMR therapeutic development solutions, we invite you to click on the link provided below.
Our Services
Preclinical research is a critical stage in the development of new PMR therapies. At our company, we offer a comprehensive range of preclinical research services to support the evaluation and validation of potential therapeutics. Our services include efficacy studies, safety assessments, pharmacokinetic evaluations, and dose optimization studies.
GCA Chimeric Models
Giant cell arteritis (GCA) is closely associated with PMR, sharing similar underlying mechanisms and genetic predispositions. To facilitate research in GCA and its interaction with PMR, Our company offers specialized GCA chimeric model development services.
Human Artery Xenograft Models
Temporal artery segments obtained from biopsy samples of PMR patients are implanted subcutaneously into nonobese diabetic (NOD)-severe combined immunodeficient (SCID) mice. Once engrafted, the arterial tissue in these mouse models sustains arteritis, closely resembling the inflammatory process observed in PMR cases.
Our company specializes in developing robust and reliable cell-based models that accurately recapitulate key features of PMR pathology. These models involve the cultivation of specific cell types involved in the disease, such as immune cells and fibroblasts, in a controlled laboratory setting.
Organoids offer three-dimensional structures that closely resemble the architecture and functionality of human organs. Our company excels in developing organoid models that accurately mimic the affected tissues in PMR, such as the synovial membrane and muscle tissue.
Result Deliver
Through rigorous preclinical testing, we aim to provide robust data and evidence to guide the selection and development of promising PMR therapies for further investigation. Beyond the aforementioned repertoire of services and models, our expertise extends to crafting personalized solutions and designing disease models that impeccably align with your unique needs. If our comprehensive range of offerings has piqued your interest, we wholeheartedly encourage you to connect with us without any hesitation.
Reference
- Lundberg Ingrid E., et al. "An update on polymyalgia rheumatica." Journal of Internal Medicine 292.5 (2022): 717-732.